Irritable bowel syndrome

Maxwell, PR; Mendall, M. A.; Kumar, Dinesh

doi:10.1016/s0140-6736(97)05276-8

Cited by 100 publications

(68 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this condition, loss of nNOS leads to pyloric hypertrophy and a complete blockade of gastric emptying. In the esophagus, loss of nNOSexpressing neurons is associated with dysfunction of the lower esophageal sphincter resulting in achalasia (68)(69)(70). Functional bowel disorders, including irritable bowel syndrome and functional dyspepsia, affect a large group of patients who may have motility disturbances (71,72).…”

Section: Discussionmentioning

confidence: 99%

Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy

Sawa²,

et al. 2000

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy

Sawa²,

et al. 2000

View full text Add to dashboard Cite

“…Although FBDs have no mortality risks, they are an important for public health because of the prevalence, negative impact on the quality of life, high cost, and failure of curative treatment (18). There is no biomarker for diagnosing FBDs, and they are diagnosed according to symptomatic criteria.…”

Section: Discussionmentioning

confidence: 99%

Functional bowel disorders and associated risk factors in hemodialysis patients in Turkey

Gök

İnci²,

Çoban³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

“…Despite this high prevalence, the cause of IBS is unknown. Many factors are likely to give rise to symptoms like those of IBS e.g., food intake, disturbances in the intestinal bacterial flora, psychosomatic influences, changed motility in the colon (Maxwell et al, 1997). All these factors by themselves or in combination can exert an effect on the motor function of the gastrointestinal tract.…”

Section: Introductionmentioning

confidence: 99%

A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial

Fan

Chen

et al. 2006

J. Zhejiang Univ. - Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome. Methods: Eighty-five patients [male 32, female 53; age (45.31±11.72) years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d.×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results: Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count (P<0.01) and lactobacillus count (P<0.05); decrease bacteroides count (P<0.05) and enterococci count (P<0.01); No obvious changes were observed in clostridium difficile colonitis and enterobacteriaceae (P>0.05). Conclusion: The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora.

show abstract

Irritable bowel syndrome

Cited by 100 publications

References 26 publications

Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy

Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy

Functional bowel disorders and associated risk factors in hemodialysis patients in Turkey

A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial

Contact Info

Product

Resources

About